{"id":69955,"date":"2026-06-15T13:38:16","date_gmt":"2026-06-15T13:38:16","guid":{"rendered":"https:\/\/www.europesays.com\/europe\/69955\/"},"modified":"2026-06-15T13:38:16","modified_gmt":"2026-06-15T13:38:16","slug":"beyond-substances-why-europe-needs-intersectional-drug-policies","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/europe\/69955\/","title":{"rendered":"Beyond Substances: Why Europe Needs Intersectional Drug Policies"},"content":{"rendered":"

The European Drug Report 2026 highlights growing drug market complexity and the need for intersectional policies rooted in public health, human rights and social inclusion.<\/p>\n

The European Drug Report 2026 <\/a>paints a picture of a rapidly evolving drug landscape in Europe. Drug availability remains high, new substances continue to emerge, and increasingly complex markets are challenging traditional approaches to prevention, treatment and law enforcement. Yet beyond the headlines about cannabis, cocaine or synthetic opioids, the report conveys a deeper message: drug-related harms are not distributed equally, and effective responses require a more nuanced understanding of vulnerability and social inequality.<\/p>\n

\"People<\/p>\n

The report stresses the need to integrate security, justice, health, and social policies to effectively address the complex impacts of drugs, particularly for vulnerable populations – Photo adapted from AlenPopov from Getty Images Signature<\/p>\n

For many years, drug policies have been organized around substances. Responses have often focused on controlling supply, reducing demand and addressing the harms associated with specific drugs. While these remain important objectives, the realities described in the European Drug Report 2026 suggest that a substance-centred perspective alone is no longer sufficient.<\/p>\n

\"\"Today\u2019s drug-related challenges are shaped by overlapping social, economic and health vulnerabilities that require more integrated and intersectional responses.<\/p>\n

Drug-related harms are not experienced equally<\/p>\n

One of the most striking themes running throughout the report is the disproportionate impact of drug-related harms on vulnerable and marginalized populations. The EUDA repeatedly highlights concerns about increasing risks among people experiencing social exclusion, homelessness, poor mental health and other forms of disadvantage.<\/p>\n

The report also draws attention to the growing involvement of young people from deprived communities in drug markets and drug-related violence. Criminal networks increasingly recruit vulnerable adolescents to carry out intimidation, assaults and other forms of violence, exploiting existing social inequalities and limited opportunities.<\/p>\n

Similarly, outbreaks of infectious diseases linked to drug use continue to disproportionately affect people who inject drugs, people experiencing homelessness and individuals facing barriers to healthcare access. Recent hepatitis outbreaks in several European countries demonstrate how social exclusion and health inequalities can amplify the impact of drug-related harms.<\/p>\n

These findings reinforce an important reality: vulnerability is not created by drugs alone. Rather, it emerges through the interaction of multiple factors, including poverty, discrimination, unstable housing, trauma, mental health challenges and limited access to support services.<\/p>\n

\"EUDA<\/p>\n

From single substances to overlapping risks<\/p>\n

Another key message from the report is that Europe\u2019s drug markets are becoming increasingly complex. The boundaries between traditional illicit drugs, new psychoactive substances, diverted medicines and synthetic compounds are becoming blurred. Consumers are often exposed to substances they did not intend to purchase, including synthetic cannabinoids, nitazenes and other highly potent compounds sold in counterfeit products or mixed into existing drug markets.<\/p>\n

At the same time, polysubstance use is becoming a defining feature of the contemporary drug landscape. The report highlights how overdose deaths frequently involve multiple substances and how combinations of stimulants, opioids, alcohol and new psychoactive substances are contributing to increasingly unpredictable health risks.<\/p>\n

This growing complexity has important policy implications. People are no longer facing risks associated with a single substance. Instead, they are navigating multiple overlapping risks that interact with broader social and health vulnerabilities.<\/p>\n

As a result, responses must move beyond fragmented approaches. Prevention, harm reduction, treatment, recovery support and social reintegration should be understood as complementary components of a continuum of care rather than isolated interventions.<\/p>\n

Policies must be capable of responding not only to substances but also to the wider circumstances that shape people\u2019s lives.<\/p>\n

Why gender still matters<\/p>\n

The report also reminds us that gender remains a critical dimension of drug policy. While women continue to be underrepresented in many datasets and services, available evidence suggests that they often face distinct barriers to accessing care and experience different patterns of stigma, violence and social exclusion.<\/p>\n

The growing concern around crack cocaine use in some European cities illustrates this point. The report notes that nearly one quarter of people entering treatment for crack-related problems are women and explicitly highlights the need for gender-responsive service provision.<\/p>\n

Gender-responsive approaches are not simply a matter of equity. They are essential for improving treatment engagement, retention and outcomes.<\/p>\n

\"Woman<\/p>\n

Drug policies that fail to address gender-based violence, caregiving responsibilities, reproductive health needs and structural discrimination risk leaving many women without appropriate support.<\/p>\n

An intersectional perspective helps us understand that gender rarely operates in isolation. Women\u2019s experiences are also shaped by class, ethnicity, migration status, housing instability and exposure to violence. Effective responses must therefore recognize these overlapping realities.<\/p>\n

Towards intersectional drug policies<\/p>\n

The European Drug Report 2026 highlights the growing complexity of Europe\u2019s drug situation. It also provides a clear indication of the direction future responses should take.<\/p>\n

Intersectional drug policies recognize that health outcomes are shaped not only by substances but also by social determinants. They place public health, human rights, gender equality and social inclusion at the centre of policy development.<\/p>\n

Such an approach means ensuring equitable access to prevention, harm reduction, treatment and recovery services. It means integrating mental health and trauma-informed care into drug responses. It means addressing stigma and discrimination as barriers to health. And it means involving people with lived and living experience in the design, implementation and evaluation of policies and services.<\/p>\n

Most importantly, it means recognizing that effective drug policy cannot be separated from broader efforts to reduce inequality and promote social justice.<\/p>\n

\"Woman<\/p>\n

Looking ahead<\/p>\n

The most important message of the European Drug Report 2026 is not that Europe has more drugs. It is that Europe faces more complex vulnerabilities.<\/p>\n

As drug markets continue to evolve, policies must evolve too. The challenges described by the EUDA demonstrate that public health, human rights, gender equality and social inclusion are not separate agendas. They are interconnected pillars of effective and humane drug policy.<\/p>\n

If risks are interconnected, our responses must be interconnected as well.<\/p>\n

At Dianova, we believe that drug policies must be grounded in public health, human rights and scientific evidence. Effective responses require a comprehensive continuum of care that includes health promotion, prevention, early intervention, harm reduction, treatment, recovery support and social reintegration.<\/p>\n

We also recognize that people experience drug-related harms differently depending on their gender, age, socio-economic circumstances, migration status, health conditions and other intersecting factors.<\/p>\n

For this reason, we advocate for gender-responsive and intersectional policies that address stigma, discrimination, trauma and social exclusion, while ensuring meaningful participation and equitable access to quality services for all. Sustainable drug policies are those that place people, dignity and social inclusion at their centre.<\/p>\n

If risks are interconnected, our responses must be interconnected as well. Public health, human rights, gender equality and social inclusion are not competing priorities; together, they form the foundation of more effective, equitable and humane drug policies.<\/p>\n","protected":false},"excerpt":{"rendered":"The European Drug Report 2026 highlights growing drug market complexity and the need for intersectional policies rooted in…\n","protected":false},"author":2,"featured_media":69956,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[39035,39036,39037,15,39038,39039,39040,39041],"class_list":["post-69955","post","type-post","status-publish","format-standard","has-post-thumbnail","category-europe","tag-drug-policies","tag-drug-related-harms","tag-euda-drug-report","tag-european","tag-european-drug-report-2026","tag-gender-responsive-approaches-to-drugs","tag-intersectional-responses","tag-polysubstance-use"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts\/69955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/comments?post=69955"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts\/69955\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/media\/69956"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/media?parent=69955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/categories?post=69955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/tags?post=69955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}